Matt’s Promise is dedicated to making a difference in the lives of young people affected by terminal illnesses. Our commitment, through select funding of treatment, research, education, and support programs, is to advance the fight against these diseases and to assure the most comprehensive, innovative, and compassionate care.
On April 21st, Sarepta Therapeutics announced that the FDA has finally provided clear guidance on a path forward for the company’s exon skipping medicines to treat Duchenne! (continues…)
Matt's Promise is a project of The Promise Foundation (EIN: 20-1618720), an organization exempt from federal income tax as a public charity.
Your contribution is tax deductible, except as may be limited under federal law.